

### **Remarks**

After entry of this amendment, claims 1-7 and 16-22 are pending, of which claims 3-6, 17, and 19-22 are currently withdrawn. Claim 1 and dependent claims are amended to recite identifying a compound that modulates cell proliferation. Representative support for these amendments was discussed in the July 20, 2007 response. No new matter is added by any of these amendments.

#### *Examiner Interview and Upcoming Examiner Interview*

Applicants thank Examiner Halvorson for taking the time to speak briefly with their undersigned representative on November 20, and for his willingness to consider this resubmission of claims. Applicants also thank the Examiner for setting up a telephone interview with the undersigned and the Examiner's Supervisor, to take place after this amendment is filed. That interview is currently scheduled for 1 PM Eastern on Thursday November 29.

#### *Arguments in Response*

Applicants incorporate herein and renew the arguments made in the July 20, 2007 Response, in rebuttal to rejections under 35 U.S.C. §§102(b) and 103(a), to the extent those arguments apply to the claims submitted herewith. It is noted that the two limitations ("H1229 cells" and "FEN1") objected to in the Advisory Action as requiring a new search are not present in the claims submitted herewith.

**Conclusion**

In view of Applicants' arguments, and the amendments submitted herewith, it is believed that the subject claims are in condition for allowance. Applicants' representative will happily discuss any remaining concerns during the Examiner Interview on November 29, 2007.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630